Regenxbio Total Assets Growth & History (RGNX)
Regenxbio's total assets was $453.0M for fiscal 2025.
View full Regenxbio company overviewRegenxbio annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $453.0M | −$13.0M | −2.78% |
| 2024 | 2024-12-31 | $466.0M | −$108.0M | −18.81% |
| 2023 | 2023-12-31 | $574.0M | −$259.3M | −31.12% |
| 2022 | 2022-12-31 | $833.3M | −$280.6M | −25.19% |
| 2021 | 2021-12-31 | $1.11B | $405.7M | +57.29% |
| 2020 | 2020-12-31 | $708.2M | $210.3M | +42.23% |
| 2019 | 2019-12-31 | $497.9M | −$45.9M | −8.44% |
| 2018 | 2018-12-31 | $543.8M | $345.1M | +173.72% |
| 2017 | 2017-12-31 | $198.7M | $25.9M | +15.02% |
| 2016 | 2016-12-31 | $172.7M | −$48.6M | −21.97% |
| 2015 | 2015-12-31 | $221.4M | $217.9M | +6241.45% |
| 2014 | 2014-12-31 | $3.5M | — | — |
Regenxbio quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $386.6M | −$194.4M | −33.46% |
| Q1 2026 | 2026-03-31 | $341.9M | −$149.0M | −30.36% |
| Q4 2025 | 2025-12-31 | $453.0M | −$13.0M | −2.78% |
| Q3 2025 | 2025-09-30 | $525.2M | $6.1M | +1.17% |
| Q2 2025 | 2025-06-30 | $581.0M | $11.6M | +2.05% |
| Q1 2025 | 2025-03-31 | $490.9M | −$138.3M | −21.98% |
| Q4 2024 | 2024-12-31 | $466.0M | −$108.0M | −18.81% |
| Q3 2024 | 2024-09-30 | $519.1M | −$114.7M | −18.09% |
| Q2 2024 | 2024-06-30 | $569.4M | −$113.1M | −16.57% |
| Q1 2024 | 2024-03-31 | $629.2M | −$118.6M | −15.86% |
| Q4 2023 | 2023-12-31 | $574.0M | −$259.3M | −31.12% |
| Q3 2023 | 2023-09-30 | $633.8M | −$250.0M | −28.29% |
| Q2 2023 | 2023-06-30 | $682.5M | −$271.0M | −28.42% |
| Q1 2023 | 2023-03-31 | $747.8M | −$277.5M | −27.07% |
| Q4 2022 | 2022-12-31 | $833.3M | −$280.6M | −25.19% |
| Q3 2022 | 2022-09-30 | $883.8M | $83.4M | +10.42% |
| Q2 2022 | 2022-06-30 | $953.4M | $117.0M | +13.99% |
| Q1 2022 | 2022-03-31 | $1.03B | $145.9M | +16.59% |
| Q4 2021 | 2021-12-31 | $1.11B | $405.7M | +57.29% |
| Q3 2021 | 2021-09-30 | $800.4M | $259.2M | +47.90% |
| Q2 2021 | 2021-06-30 | $836.4M | $386.7M | +85.98% |
| Q1 2021 | 2021-03-31 | $879.4M | $415.5M | +89.56% |
| Q4 2020 | 2020-12-31 | $708.2M | $210.3M | +42.23% |
| Q3 2020 | 2020-09-30 | $541.2M | $31.9M | +6.27% |
| Q2 2020 | 2020-06-30 | $449.7M | −$79.4M | −15.01% |
| Q1 2020 | 2020-03-31 | $463.9M | −$55.1M | −10.61% |
| Q4 2019 | 2019-12-31 | $497.9M | −$45.9M | −8.44% |
| Q3 2019 | 2019-09-30 | $509.2M | −$5.7M | −1.12% |
| Q2 2019 | 2019-06-30 | $529.1M | $193.2M | +57.49% |
| Q1 2019 | 2019-03-31 | $519.0M | $201.8M | +63.62% |
| Q4 2018 | 2018-12-31 | $543.8M | $345.1M | +173.72% |
| Q3 2018 | 2018-09-30 | $515.0M | $305.7M | +146.10% |
| Q2 2018 | 2018-06-30 | $336.0M | $111.6M | +49.74% |
| Q1 2018 | 2018-03-31 | $317.2M | $93.1M | +41.53% |
| Q4 2017 | 2017-12-31 | $198.7M | $25.9M | +15.02% |
| Q3 2017 | 2017-09-30 | $209.3M | $13.3M | +6.78% |
| Q2 2017 | 2017-06-30 | $224.4M | $18.3M | +8.88% |
| Q1 2017 | 2017-03-31 | $224.1M | $9.1M | +4.25% |
| Q4 2016 | 2016-12-31 | $172.7M | −$48.6M | −21.97% |
| Q3 2016 | 2016-09-30 | $196.0M | −$31.3M | −13.79% |
| Q2 2016 | 2016-06-30 | $206.1M | — | — |
| Q1 2016 | 2016-03-31 | $215.0M | — | — |
| Q4 2015 | 2015-12-31 | $221.4M | $217.9M | +6241.45% |
| Q3 2015 | 2015-09-30 | $227.3M | — | — |
| Q4 2014 | 2014-12-31 | $3.5M | — | — |
Regenxbio total assets trends
Over the last five fiscal years, Regenxbio's total assets decreased from $708.2M to $453.0M, a change of −$255.1M. The latest reported quarter, Q2 2026, shows $386.6M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗